{"brief_title": "Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.", "brief_summary": "To evaluate the safety and efficacy of itraconazole oral solution versus fluconazole tablets for the treatment of esophageal candidiasis in immunocompromised patients.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Fluconazole", "criteria": "Inclusion Criteria Patients must have: - Esophageal candidiasis. - Histological evidence of Candida spp. at baseline with confirmation by positive mycological culture. - HIV infection or other predisposing risk factor. - Life expectancy of at least 2 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Malignancies of the head or neck, if the treatment or disease will interfere with response assessment. - Evidence of systemic fungal infection. - Underlying clinical condition that would preclude study completion. - Judged to be unreliable in regard to following physician's directives. Concurrent Medication: Excluded: - Rifampin. - Rifabutin. - Phenobarbital. - Phenytoin. - Carbamazepine. - Terfenadine. - Astemizole. - H2 blockers. - Continual antacids. - Any investigational drug (expanded access drugs are allowed). Patients with the following prior conditions are excluded: - History of significant hepatic abnormalities or clinical evidence of hepatic disease within 2 months prior to study entry. - History of hypersensitivity to imidazole or azole compounds. Prior Medication: Excluded: - Other orally administered antifungal therapy within 3 days prior to study entry. - Any investigational drug within 1 month prior to study entry (expanded access drugs are allowed).", "gender": "All", "minimum_age": "13 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002132.xml"}